Our results using these CAIX inhibitory compounds are supported by other recent findings reporting decreases in both primary tumor growth and metastasis in several preclinical breast tumor models with no signs of non-specific toxicity [25, 40, 46]. This evidence concerns the gene CA9 and neoplasm.